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Phosphorylation of the RelA (p65) NF-κB (nuclear factor κB)
subunithasbeenpreviouslyshowntomodulateitsabilitytoinduce
or repress transcription. In the present study we have investigated
the consequences of Thr
435 phosphorylation within the
C-terminaltransactivationdomainofRelA.WeconﬁrmthatThr
435
is phosphorylated in cells and is induced by TNFα (tumour
necrosis factor α) treatment. Mutational analysis of this site
revealed gene-speciﬁc effects on transcription, with a T435D
phosphomimetic mutant signiﬁcantly enhancing Cxcl2 (CXC
chemokineligand2)mRNAlevelsinreconstitutedRela
−/− mouse
embryonic ﬁbroblasts. Chromatin immunoprecipitation analysis
revealed that this mutation results in enhanced levels of histone
acetylation associated with decreased recruitment of HDAC1
(histone deacetylase 1). Moreover, mutation of this site disrupted
RelA interaction with HDAC1 in vitro.T h r
435 phosphorylation
of promoter-bound RelA was also detected at NF-κBt a r g e t
genes following TNFα treatment in wild-type mouse embryonic
ﬁbroblasts. Phosphorylation at this site therefore provides an
additional mechanism through which the speciﬁcity of NF-κB
transcriptional activity can be modulated in cells.
Key words: CXC ligand 2 (CXCL2)/macrophage inﬂammatory
protein 2 (MIP2), histone acetylation, histone deacetylase 1
(HDAC1), nuclear factor κB (NF-κB), RelA (p65), tumour
necrosis factor α (TNFα).
INTRODUCTION
Members of the NF-κB (nuclear factor κB) transcription factor
family are known to regulate a variety of cellular processes
including inﬂammatory and immune responses, cell survival,
cell differentiation and cell proliferation [1]. Furthermore,
dysregulation of NF-κB signalling has been implicated in
the development and progression of a multitude of diseases,
particularly conditions involving chronic inﬂammation or
compromised immunity and cancer [2,3]. Mammalian NF-κB
is a multigene family composed of ﬁve members capable of
formingavarietyofhomo-andhetero-dimericcomplexesthrough
their highly conserved N-terminal Rel homology domain [4].
In unstimulated cells, NF-κB dimers are primarily found as
inactive, cytoplasmic complexes. Classical activation of NF-κB
occurs in a well-deﬁned IκB (inhibitor of NF-κB)-kinase-
dependent manner, typically culminating in the release of
RelA/p50 heterodimers from inhibitory IκB proteins, enabling
dimer translocation to the nucleus and transcriptional modulation
of NF-κB target genes [5].
The RelA (p65) subunit contains a potent TAD (transactivation
domain), which allows recruitment of co-transcriptional
regulators and components of the basal transcriptional machinery
to gene targets [6]. Numerous post-translational modiﬁcations to
RelA have been reported and varying effects on transcriptional
activity, protein interactions, stability and degradation have been
demonstrated [7]. Phosphorylation of sites within the TAD of
RelAleadtobothincreasedanddecreasedlevelsoftranscriptional
activity, with the precise effect dependent on the context and gene
target [8–20]. The effects these modiﬁcations exert on protein–
protein interactions has not been studied extensively. However,
site-speciﬁc phospho-dependent increased binding to the co-
transcriptional regulators TAFII31 (TATA-box-binding-protein-
associatedfactor31)andHDAC1(histonedeacetylase1)hasbeen
shown [9,11]. Additionally, components of the ubiquitin ligase
complex COMMD1 and cullin 2 were found to bind to RelA via
GCN5 in a phospho-site-speciﬁc manner, thereby directing RelA
ubiquitination and degradation at certain promoters following
TNFα (tumour necrosis factor α) stimulation [13,16].
The mechanisms behind the ability of RelA to speciﬁcally
regulate endogenous target-gene expression are continually being
uncovered. Activation of certain endogenous target genes was
recently shown to occur by two distinct modes, one involving
the direct interaction of RelA with the Trap-80 mediator complex
subunitandsubsequentrecruitmentofPolII(RNApolymeraseII),
and the other via RelA’s ability to regulate promoter occupancy
of secondary transcription factors [21]. The murine chemokine
Cxcl2 [CXC ligand 2/MIP2 (macrophage inﬂammatory protein
2)] was found to be regulated in a Trap-80-independent manner
and RelA was shown to regulate the recruitment of the secondary
transcription factor SP1 to this promoter [21]. In the present
paper, we present evidence for the ability of RelA to induce
changes in the acetylation state of histones at the Cxcl2 promoter.
Furthermore, we demonstrate that this effect is inﬂuenced by
phosphorylation at Thr
435 within RelA’s TAD, which modulates
the interaction of RelA with HDAC1.
EXPERIMENTAL
Cell culture
Human U-2 OS osteosarcoma cells and HEK-293 cells (human
embryonic kidney cells) were obtained from the A.T.C.C.
(American Type Culture Collection). Immortalized MEF (mouse
embryonic ﬁbroblast) cells and immortalized Rela
−/− MEFs
were provided by Professor R. Hay, College of Life Sciences,
Abbreviations used: CBP, cAMP-response-element-binding protein-binding protein; ChIP, chromatin immunoprecipitation; CK2, casein kinase 2; CXCL2,
CXC ligand 2; DBD, DNA-binding domain; EMSA, electrophoretic mobility-shift assay; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HAT,
histone acetyltransferase; HDAC1, histone deacetylase 1; HEK-293 cells, human embryonic kidney cells; IκB, inhibitor of NF-κB; IL, interleukin; LPS,
lipopolysaccharide; MEF, mouse embryonic ﬁbroblast; MIP2, macrophage inﬂammatory protein 2; NF-κB, nuclear factor κB; PARP, poly(ADP-ribose)
polymerase; Pol II, RNA polymerase II; PP4, protein phosphatase 4; qPCR, quantitative PCR; TAD, transactivation domain; TAFII31, TATA-box-binding-
protein-associated factor 31; TNFα, tumour necrosis factor α.
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UniversityofDundee,Dundee,U.K.RelA-nullMEFswerestably
reconstituted with vector alone (control), wild-type RelA (RelA),
or RelA with Thr
435 mutated to an alanine residue (T435A) or an
asparticacidresidue(T435D).StablyreconstitutedRela
−/− MEFs
were selected with 2 μg/ml puromycin (Sigma) and subsequently
maintained in 0.5 μg/ml puromycin.
Preparation of viral stocks
Viral stocks for lentiviral infections were generated by
transfecting 5 μg of viral envelope (pCMV-VSV-G), packaging
(pCMV R8.91) and vector (PIRESpuro-deNotI and derivatives)
plasmids(providedbyProfessorR.Hay,CollegeofLifeSciences,
University of Dundee, Dundee, U.K., and Professor M. Collins,
DepartmentofImmunology,UniversityCollegeLondon,London,
U.K.) into HEK-293 cells. Medium containing the viral stocks
was removed after 48 h. The medium was centrifuged at 350 g
for 3 min and ﬁltered through a 0.45 μm ﬁlter to remove cells.
Viral stocks were then divided into aliquots (1ml), snap-frozen
a n ds t o r e da t−80◦C.
Generation of stable cells
Infections were performed by mixing 4 μg/ml polybrene (Sigma)
with 30 μl of virus stock in a total volume of 3 ml of medium.
T h i sw a su s e dt oi n f e c ta5 0% conﬂuent 10-cm-diameter plate of
Rela
−/− MEFs by incubating overnight at 37◦C. On the second
day, the medium containing the virus was removed and the plate
was washed twice with PBS before the addition of fresh medium.
On the third day, the cells were split 1:5. On the fourth day,
cells were selected by replacing the medium with puromycin-
containing medium (2 μg/ml), and when all cells in the mock
infectionplatehaddiedthepuromycinconcentrationwaslowered
to 0.5 μg/ml. This concentration was used to maintain stably
expressing cell lines. In all experiments, pools of reconstituted
MEF cells were used.
qPCR (quantitative PCR)
qPCRs were performed on Rotor-Gene 3000 and 6000 machines
(Corbett Research). Ct values (threshold cycle values) were
calculated using Rotor-Gene 6 software and all values were
calculated relative to GAPDH (glyceraldehyde-3-phosphate
dehydrogenase) or input levels using the Pfafﬂ method [22].
Primers
RT–PCR (reverse transcription–PCR)
Primers used were: Bcl2l1 (Bcl-xl) (FWD 5
 -GATGCAGGTA-
TTGGTGAGTCG-3
 ,R E V5
 -GCTCTCGGCTGCTGCATT-3
 );
Cxcl1 (KC) (FWD 5
 -CTGGGATTCACCTCAAGAAC-3
 ,R E V
5
 -GAAGCCAGCGTTCACCAGAC-3
 ); Cxcl2 (MIP2) (FWD
5
 -TCAAGGGCGGTCAAAAAGTT-3
 ,R E V5
 -TCCTCCTTT-
CCAGGTCAGTTA-3
 ); Cxcl3 (FWD 5
 -CCTACCAAGGGTT-
GATTT-3
 ,R E V5
 -CGCTCTTCAGTATCTTCTT-3
 ); Cxcl4
(Pf4) (FWD 5
 -GAAAGCGATGGAGATCTTA-3
 ,R E V5
 -TCT-
TATATAGGGGTGCTTGC-3
 ); Cxcl5 (GCP-2) (FWD 5
 -CATT-
TCTGTTGCTGTTCA-3
 ,R E V5
 -GGGATCACCTCCAAAT-
TA-3
 ); Cxcl7 (Ppbp) (FWD 5
 -CTTCATAACCTCCAGATCTT-
3
 ,R E V5
 -ACACATTCACAAGGGAGATA-3
 ); Cxcl10 (IP-10)
(FWD 5
 -CCAAGTGCTGCCGTCATTTTC-3
 ,R E V5
 -GGCT-
CGCAGGGATGATTTCAA-3
 ); Cxcl11 (FWD 5
 -AGGAAG-
GTCACAGCCATAG-3
 ,R E V5
 -CTCGATCTCTGCCATTTT-
3
 ); Cxcl12 (FWD 5
 -CATCTGAAAATCCTCAACACT-3
 ,R E V
5
 -AAGCTTTCTCCAGGTACTCT-3
 ); Gapdh (FWD 5
 -GC-
TACACTGAGGACCAGGTTG-3
 ,R E V5
 -GCCCCTCCTG-
TTATTATGGGG-3
 ); and Tnfaip3 (A20) (FWD 5
 -GAACAGC-
GATCAGGCCAGG-3
 ,R E V5
 -GGACAGTTGGGTGTCTCA-
CATT-3
 ).
ChIP (chromatin immunoprecipitation)
Primers used were: Cxcl1 (FWD 5
 -CTAATCCTTGGGAGTG-
GAG-3
 ,R E V5
 -CCCTTTTATGCTCGAAAC-3
 ); Cxcl2 (FWD
5
 -CGTGCATAAAAGGAGCTCTC-3
 ,R E V5
 -GTGCCCGAG-
GAAGCTTGT-3
 ); and Tnfaip3 (FWD 5
 -CGCTGAGAGAGA-
GACAAAC-3
 ,R E V5
 -TGGCCCTGAAGATTAACT-3
 ).
Antibodies
Antibodies used were anti-RelA antibody (sc-372; Santa Cruz
Biotechnology), anti-Gal4 (DBD; DNA-binding domain) anti-
body (sc-577; Santa Cruz Biotechnology), anti-β-actin antibody
(A5441; Sigma), anti-PARP [poly(ADP-ribose) polymerase]
antibody (9542; Cell Signaling Technology), anti-Pol II antibody
(sc-56767; Santa Cruz Biotechnology), anti-SP1 antibody (sc-
59; Santa Cruz Biotechnology), anti-acetyl histone H3 antibody
(06-599; Upstate), anti-acetyl histone H4 antibody (ab-1761;
Abcam), anti-HDAC1 antibody (06-720; Upstate), anti-PK-
TAG/V5-TAG antibody (MCA1360GA; AbD Serotec), and
anti-HA-TAG antibody (2367; Cell Signaling Technology).
The RelA Thr
435 phospho-speciﬁc antibody was raised in
rabbit by BioGenes. The peptide used had the sequence
TQAGEGT*LSEALC (phospho-Thr
435 is indicated by *).
The antibody was puriﬁed using two-step peptide afﬁnity
chromatography with the phospho- and non-phospho-peptides.
ELISA analysis conﬁrmed that the puriﬁed antibody was speciﬁc
for the phosphorylated epitope.
Plasmids
The Gal4 E1B and 3× κB ConA luciferase reporter plasmids,
along with the Gal4–RelA-TAD, RSV RelA and HA–HDAC1
expression plasmids, have been reported previously [18,23].
The viral envelope (pCMV-VSV-G), packaging (pCMV R8.91)
and vector (PIRESpuro-deNotI) plasmids were obtained from
Professor R. Hay (College of Life Sciences, University of
Dundee, Dundee, U.K.) and Professor M. Collins (Department
of Immunology, University College London London, U.K.). The
Cxcl2 (MIP2) luciferase reporter plasmid was obtained from
Professor M. Hottiger (Institute of Veterinary Biochemistry and
Molecular Biology, University of Z¨ urich, Z¨ urich, Switzerland)
[24]. PK-tagged RelA was generated by inserting an N-terminal
PK-TAG into pcDNA3.1 vector. All point mutations were
generated by PCR overlap extension, except for the Gal4-fusion
mutants, which were generated in a single PCR step, and were
sequenced prior to use.
Other assays
ChIP, co-immunoprecipitation, reporter-gene assays, Western
blot analysis and EMSA (electrophoretic mobility-shift assay)
analysis were performed essentially as described previously
[18,25,26].
RESULTS
RelA Thr435 is phosphorylated following calyculin A and TNFα
treatment
PP4 (protein phosphatase 4)-mediated Thr
435 dephosphorylation
was previously proposed to enhance RelA-mediated activation
following cisplatin treatment, implying that phosphorylation at
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Figure 1 RelA Thr435 is a phospho-site that affects TAD activity
(A) U-2 OS cells were stimulated for the indicated times with calyculin A (50nM). A portion of whole cell extract (40μg) was analysed by Western blotting (WB) using the anti-phospho-Thr435
(α P-T435) or anti-RelA (α RelA) antibodies (upper panel). Whole cell extract (350μg) was immunoprecipitated (IP) with anti-RelA antibody and samples were analysed by Western blotting with
the anti-phospho-Thr435 antibody (lower panel). Membranes were then stripped and reprobed with total RelA antibody. (B) U-2 OS cells were stimulated with calyculin A (50nM) for 15 min or
TNFα (20ng/ml) as indicated. A portion of whole cell extract (40μg) was analysed by Western blotting with the anti-phospho-Thr435 antibody. The membrane was then stripped and reprobed with
total anti-RelA antibody. Densitometry analysis indicates an increase in intensity of the phospho-band in relation to the untreated sample, normalized to RelA input levels. Anti-β-actin antibody
(αβ -actin) was used as a loading control. (C) MEF cells were stimulated with TNFα (20ng/ml) as indicated. Whole cell extract (100μg) was immunoprecipitated with the anti-phospho-Thr435
antibody and samples were analysed by Western blotting with total anti-RelA antibody. Anti-IgG antibody (α IgG) was used to control for non-speciﬁc binding. (D) U-2 OS cells were transfected with
1.5 μg of Gal4 E1B luciferase reporter plasmid and 750 pg of expression plasmid encoding the Gal4 DBD, the Gal4 DBD fused to amino acids 428–551 of RelA (RelA TAD), amino acids 428–551 of
RelA with Thr435 mutated to an alanine residue (T435A) or amino acids 428–551 of RelA with Thr435 mutated to an aspartic acid residue (T435D). A Western blot demonstrating expression levels
of Gal4 fusion proteins is shown. Luciferase assay results are expressed as fold-activation over Gal4 DBD control, relative to wild-type RelA TAD. Results are means+ −S.E.M., n=8. ANOVA was
performed followed by a Tukey–Kramer multiple comparisons test using Prism 4 software (GraphPad). *P <0.05 and ***P <0.001 compared with wild-type TAD. (E) U-2 OS cells were transfected
with 1 μgo f3 × κB ConA luciferase reporter plasmid and 0.6μg of expression plasmid encoding empty RSV vector, full-length wild-type RelA (RelA), RelA with Thr435 mutated to alanine (T435A)
or RelA with Thr435 mutated to aspartic acid (T435D). A Western blot demonstrating expression levels of RelA proteins is shown. Luciferase-assay results are expressed as fold-activation over empty
RSV plasmid. Results are the means+ − S.E.M., n=3. ANOVA was performed followed by a Tukey–Kramer multiple comparisons test using Prism 4 software (GraphPad).
this site has a negative effect on the activity of RelA [27].
In order to determine the phosphorylation status of Thr
435 in
cells, a phospho-speciﬁc antibody against this site was raised,
and ELISA analysis conﬁrmed that the puriﬁed antibody was
speciﬁc for this phosphorylated epitope (results not shown).
Treating U-2 OS osteosarcoma cells with the serine/threonine
phosphatase inhibitor calyculin A resulted in increasing levels
of phosphorylation at this site that were masked by background
bands in direct Western blots, but were clearly visible after
immunoprecipitation with an anti-RelA antibody (Figure 1A).
It was subsequently found that there was weak induction of
phosphorylation at this site in U-2 OS cells following stimulation
with the well-characterized NF-κB activator TNFα (Figure 1B).
However, rapid Thr
435 phosphorylation was detected in MEF cells
following TNFα stimulation (Figure 1C).
Role of Thr435 on RelA transcriptional activity
To investigate potential effects on the transcriptional activity of
RelA mediated through the Thr
435 residue, both phospho-null
(T435A) and phospho-mimicking (T435D) mutations of this site
were created. These mutants were initially generated as TAD-
fusion proteins with the DBD of Gal4, thereby allowing only
TAD-dependent effects to be investigated. Signiﬁcantly, when
transfected into U-2 OS cells, the T435A mutation resulted in a
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Figure 2 Creation of stable cell lines constitutively expressing wild-type and mutant forms of RelA
(A) Western blot analysis of RelA protein levels in stably reconstituted Rela−/− MEFs. α RelA, anti-RelA antibody; αβ -actin, anti-β-actin antibody. (B) Introduction of RelA protects cells from
TNFα-induced cell death. Whole cell extracts were prepared from reconstituted MEF cells stably expressing wild-type and mutant forms of RelA, either unstimulated or stimulated with TNFα
(40ng/ml)for4h.WesternblotanalysiswasperformedforPARPcleavage.α PARP,anti-PARPantibody.(C)TNFα-inducedDNAbindingwasnotaffectedbymutatingThr435.Nuclearproteinextracts
werepreparedfromreconstitutedMEFcellsstimulatedwithTNFα (40ng/ml)fortheindicatedtimes,and5μgofnuclearextractwassubjectedtoEMSAanalysisusing 32P-labelledoligonucleotides
containing the IL-8 κB element or the Oct1 transcription factor-binding site as a loading control.
dramaticincreaseintranscriptionalactivity,whereasthephospho-
mimicking T435D mutation decreased activity, indicating that
phosphorylation at this site may repress the transcriptional
potential of the RelA TAD (Figure 1D). To further investigate
these transcriptional effects, full-length versions of these mutants
were created. However, the dramatic differences in activity
observed with the Gal4 reporter were not reciprocated in
RelA-dependent reporter assays, and no signiﬁcant differences
in transcriptional activity were found following the mutation
of Thr
435, either in the context of a 3× κB ConA luciferase
reporter plasmid (Figure 1E) or DR5, IκB or IL (interleukin)-8
reporter constructs (results not shown). Taken together, these
results indicate that strong transcriptional modulation of the TAD
occurs through Thr
435, but effects mediated through this residue
may be speciﬁc for certain gene targets.
Creating stably reconstituted wild-type and Thr435-mutant RelA cell
lines
To further investigate effects on RelA activity, full-length wild-
type and Thr
435-mutant forms of RelA were stably introduced
into Rela
−/− MEFs, using a lentiviral infection approach. This
approach also prevented effects of mutant RelA proteins being
obscured by endogenous wild-type RelA. Pools of cells stably
expressing wild-type and mutant forms of RelA at equivalent
levels were generated (Figure 2A).
It is known that deletion of Rela results in embryonic lethality
from extensive foetal hepatocyte apoptosis, due to increased
sensitivity to TNFα [28]. Loss of RelA also sensitizes MEFs
to TNFα-induced cell death and this can be rescued by stably
expressingRelA[29].Boththewild-typeandThr
435-mutantRelA
reconstituted cells were rescued from TNFα-induced apoptotic
cell death, as revealed by the absence of PARP cleavage, an
indicator of caspase-mediated cell death (Figure 2B), indicating
that phosphorylation at this site is unlikely to affect this important
function of RelA [30].
Stimulation with TNFα induces the activation of the canonical
NF-κB pathway, resulting in the rapid translocation of RelA
complexes to the nucleus of the cell and enhanced DNA binding
to κB sites in responsive genes, such as IL-8 [1,31]. DNA binding
in response to canonical pathway activation in the reconstituted
cells were investigated by EMSA analyses. Although a low level
of basal NF-κB DNA binding to an IL-8 κB oligonucleotide
could be seen in unstimulated RelA reconstituted cells, this was
signiﬁcantly induced following TNFα stimulation (Figure 2C).
Furthermore, mutating Thr
435 did not affect TNFα-induced DNA
binding.Thereforethesereconstitutedcelllinescontainfunctional
TNFα-inducibleRelA,capableofregulatingtheexpressionofthe
anti-apoptoticgenesnecessaryforrescuefromTNFα-inducedcell
death.
Regulation of NF-κB gene targets
To analyse the potential effects mediated through Thr
435 on
known NF-κB gene targets, qPCR analysis was performed
on cDNA generated from these reconstituted cell lines. Initially,
known NF-κB target genes, Bcl2l1 (Bcl-xl), Cxcl1 (KC),
Cxcl2 (MIP2) and Tnfaip3 (A20) [32–35], were investigated
in unstimulated cells to allow analysis of Thr
435 mutation on
basal level expression. In agreement with previous studies,
expression of the chemokines Cxcl1 and Cxcl2 was severely
diminished in the absence of RelA and was found to be enhanced
following reconstitution with all forms of RelA (Figures 3A
and 3B) [21,33,35]. However, some differences between the
Thr
435-mutant forms of RelA were observed. Cxcl2 expression
was dramatically increased in the phospho-mimicking T435D
cell line, indicating that phosphorylation at this site may play
a role in the induction of this gene (Figure 3A). In agreement
with this, a Cxcl2 promoter luciferase-reporter plasmid was
also found to have higher expression levels with the T435D
mutant (Figure 3E). Similar enhancement of mRNA expression
by the T435D mutation was not observed for other members
of the CXC chemokine superfamily whose expression was
detectable in these cell lines (see Supplementary Figure S1
at http://www.BiochemJ.org/bj/426/bj4260345add.htm). Expres-
sion levels of the CXC chemokine Cxcl1 were signiﬁcantly
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Figure 3 Regulation of endogenous NF-κB target genes
(A) Introduction of RelA into Rela−/− MEFs increases expression levels of Cxcl2 (MIP2).
Inserting a T435D mutation further enhances this effect. (B) Introduction of RelA into Rela−/−
MEFs increases expression levels of Cxcl1 (KC). (C) Introduction of RelA increases expression
levels of Tnfaip3 (A20). (D) Introduction of RelA reduces expression levels of Bcl2l1 (Bcl-xl).
RNA was extracted from reconstituted MEF cells, total cDNA was prepared and qPCR analysis
was performed using primers to mouse Cxcl2, Cxcl1, Tnfaip3, Bcl2l1 and Gapdh control. All
results are normalized to Gapdh levels and expressed as fold-induction relative to the level
of gene expression in the control cell line. (E) U-2 OS cells were transfected with 0.5μg
of Cxcl2 luciferase reporter plasmid and 0.5 μg of expression plasmid encoding empty RSV
vector,full-lengthwild-typeRelA(RelA),RelAwithThr435 mutatedtoanalanineresidue(T435A)
and RelA with Thr435 mutated to an aspartic acid residue (T435D). Results are expressed as
fold-activation over empty RSV plasmid. Results are the means+ −S.E.M.; (A–D) n=4, (E)
n=3. ANOVA was performed followed by a Tukey–Kramer multiple comparisons test using
Prism4software(GraphPad).*P <0.05,**P <0.01and***P <0.001.Greyasterisksindicate
P values relative to the control cell line.
reduced in the unphosphorylatable T435A cell line, suggesting
that phosphorylation at this site is important for basal expression
of this gene (Figure 3B). Levels of the ubiquitin-editing enzyme
Tnfaip3 also became elevated following the introduction of RelA,
butnosigniﬁcantdifferencesweredetectedbetweenthewild-type
andThr
435-mutantcelllines(Figure3C).Finally,expressionofthe
anti-apoptotic gene Bcl2l1 was reduced following reconstitution
with RelA (Figure 3D).
Taken together, these results indicate that the Thr
435 residue
regulatesthetranscriptionalactivityoffull-lengthRelAinagene-
speciﬁc manner. To begin a more mechanistic evaluation of these
effects, the role played by the T435D mutant in the up-regulation
of Cxcl2 expression levels was investigated using ChIP analysis.
Protein occupancy at the Cxcl2 promoter in reconstituted cell lines
Increased expression of the murine Cxcl2 gene is known to
occur in a RelA-dependent manner, following exposure to a
variety of NF-κB-inducing stimuli, including TNFα,L P S
(lipopolysaccharide) and hypoxia [21,33,36,37]. The Cxcl2
promoter contains not only an NF-κB-binding motif, but also
SP1- and AP1-binding motifs, all of which are required for
optimal promoter activation [36,38]. ChIP analysis revealed
that in unstimulated cells, consistent with enhanced levels of
gene expression, elevated levels of RelA, Pol II and SP1
were found at the Cxcl2 promoter in the T435D cell line
(Figures 4A–4C). In contrast, enhanced binding of the T435D
mutant form of RelA was not observed at either the Cxcl1
or Tnfaip3 promoters (see Supplementary Figures 2A and
2B at http://www.BiochemJ.org/bj/426/bj4260345add.htm). This
indicatedthatCxcl2-promoter-speciﬁcrecruitmentisregulatedby
theT435DmutationandthatthisisnotanintrinsiceffectonDNA
binding, consistent with the earlier EMSA analysis (Figure 2C).
Next, we examined effects on histone modiﬁcation at the Cxcl2
promoter, and enhanced acetylation of histones H3 (Lys
9 and
Lys
14) and H4 (Lys
12), both being markers for active regions of
transcription, were observed following the introduction of wild-
typeRelAortheT435Dmutant(Figures4Dand4E).IntheT435D
cells, acetylated histone H3 levels were higher than those found
in the phospho-null T435A cells, but not signiﬁcantly higher
thaninthewild-typeRelAcells(Figure4D).However,acetylated
histone H4 levels were signiﬁcantly higher in the T435D cells,
comparedwithbothwild-typeRelAandT435A-mutantcells,con-
sistent with increased expression of this gene in the T435D cell
line (Figure 4E). To determine whether the reduced acetylation
detected in the T435A cell line results from enhanced binding of
a deacetylase enzyme, levels of HDAC1 binding to the Cxcl2 pro-
moterweredetermined,andenhancedHDAC1bindingwasdetec-
tedatthispromoter(Figure4F).Theseresultsillustratethatmutat-
ing Thr
435, which is located in the TAD of RelA, inﬂuences the
abilityofRelAandothertranscriptionfactors,suchasSP1andPol
II, to bind speciﬁcally to the Cxcl2 promoter. Additionally, differ-
encesintheacetylationstatusofhistonetailsatthispromoterwere
alsodetectedandcanbeaccountedfor,atleastinpart,byelevated
levels of HDAC1 binding to the promoter in the T435A cell line.
HDAC1 interaction with RelA
To investigate potential differences in HDAC1 interaction with
RelA, co-immunoprecipitation analyses were performed using
PK-tagged wild-type and Thr
435-mutant forms of RelA, along
with HA-tagged HDAC1. Signiﬁcantly, the phospho-mimicking
T435D mutation decreased HDAC1 interaction with RelA
(Figure4G),corroboratingresultsobtainedthroughChIPanalysis
oftheCxcl2promoter(Figure4F).AsTNFα stimulationisknown
to result in decreased HDAC1 interaction with RelA [39], this
result is consistent with Thr
435 phosphorylation contributing to
this process.
Regulation of NF-κB gene targets following TNFα stimulation
Taken together, these results suggested that the effect of the
T435D mutation was to mimic the effect of TNFα stimulation
on the RelA-dependent regulation of Cxcl2 expression. Therefore
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Figure 4 ChIP analysis of the murine Cxcl2 promoter in reconstituted cell lines
(A–C) Elevated levels of RelA (A) ,P o lI I( B) and SP1 (C) were detected at the Cxcl2 initiation site in the T435D cell line by qPCR. (D, E) Introducing wild-type RelA and T435D increases acetylation
(Ac) of both histone H3 (K9/14) and histone H4 (K12). Creating a T435A mutation does not signiﬁcantly increase the acetylation at this promoter. (F) Enhanced binding of HDAC1 to the Cxcl2
promoter in the T435A cell line. qPCR analysis was performed using primers to the mouse Cxcl2 initiation site. All results were normalized to input levels and control antibodies. Results are the
mean enrichment levels relative to the control cell line+ −S.E.M.; (A) n=5, (B) n=3, (C) n=6, (D) n=3, (E) n=4, (F) n=7. ANOVA was performed followed by a Tukey–Kramer multiple
comparisons test using Prism 4 software (GraphPad). *P <0.05, **P <0.01 and ***P <0.001. Grey asterisks indicate P values relative to the control cell line. (G) HDAC1 interaction with RelA is
reduced by mimicking phosphorylation at Thr435. Co-immunoprecipitation (IP) analysis of the HDAC1 interaction with wild-type and Thr435-mutant forms of RelA was performed using the antibodies
indicatedandwholecellextracts(300μg)fromHEK-293cellstransfectedwithexpressionplasmidencodingHA–HDAC1andPK,PK–RelA,PK–T435AorPK–T435D.Aportionofwholecellextracts
(20μg) was included as input. WB, Western blot.
we next investigated the effects of TNFα stimulation on the
RelA-reconstitutedMEFs.ARelA-dependentTNFα-inducedup-
regulation of both Cxcl1 and Cxcl2 was observed (Figures 5A
and 5B). In the case of Cxcl1, this induction resulted in similar
levels of mRNA in the reconstituted cells, bypassing the reduced
basal expression seen in the T435A cell line. However, in the
case of Cxcl2, there were differences in the induction of this
genebetweentheThr
435 mutants.Cellscontainingwild-typeRelA
showed a robust induction in Cxcl2 mRNA levels, reaching levels
similartothatfoundbasallyintheT435Dcellline,suggestingthat
this mutation did indeed mimic the effects of TNFα stimulation
for this NF-κB gene target. This increase was much reduced in
cells containing the T435A mutant. The already enhanced levels
of expression seen with the T435D mutant were stimulated
somewhat further by TNFα treatment, as might be expected
from the enhanced translocation of RelA to the nucleus under
these conditions. These results are consistent with RelA Thr
435
phosphorylation playing an important role in the TNF-dependent
induction of Cxcl2 expression.
Effects on other NF-κB target genes were also examined. RelA
also enhanced Tnfaip3 expression following TNFα treatment, but
signiﬁcant differences were not detected between wild-type and
Thr
435 mutants (Figure 5C). However, TNFα had little effect on
Bcl2l1 mRNA levels (Figure 5D). This result is consistent with
ChIP analysis, where we could not observe RelA binding to the
Bcl2l1 promoter in the reconstituted MEF cell lines (results not
shown), suggesting that in this context this gene is not a RelA
target and the effects we see on its expression are indirect. We
also examined the expression levels of the other members of the
CXC chemokine superfamily expressed in these cells, before and
afterTNFα stimulation(SupplementaryFigureS1).Interestingly,
although some effects with Thr
435 mutation are seen, these are
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Figure 5 Expression levels of NF-κB target genes following TNFα treatment
(A–C) TNFα stimulation differentially increases mRNA levels of Cxcl2, Cxcl1 and Tnfaip3 in the reconstituted cells. (D) TNFα stimulation does not signiﬁcantly alter the expression of Bcl2l1 in the
reconstituted cells. RNA was extracted from reconstituted MEF cells, either unstimulated or stimulated with TNFα (40ng/ml) for 30 min. Total cDNA was prepared and qPCR analysis was performed
using primers to mouse (A) Cxcl2,( B) Cxcl1,( C) Tnfaip3,( D) Bcl2l1 and Gapdh control. All results were normalized to Gapdh levels and are expressed as fold-induction relative to the level of gene
expression in the control cell line. Results are the means+ −S.E.M., n=3. Two-way ANOVA was performed followed by a Bonferroni post-hoc test to compare replicate untreated and TNFα means,
using Prism 4 software (GraphPad). *P <0.05 and **P <0.01.
associated with reductions in the levels of gene expression (e.g.
see Cxcl3 and Cxcl7). However, in this analysis, no other genes
were found with the enhanced levels of expression seen with
Cxcl2 that are associated with Thr
435 phosphorylation. This
conﬁrmedthat,inthiscontext,theeffectofThr
435 phosphorylation
on RelA-dependent gene expression is highly speciﬁc.
Protein occupancy at the Cxcl2 promoter in wild-type MEFs
Next, we investigated endogenous RelA binding to the Cxcl2
promoterinwild-typeMEFs.Asexpected,ChIPanalysisrevealed
enhancedRelAbindingfollowingTNFα stimulation(Figure6A).
Importantly, and consistent with its predicted role as a regulator
of Cxcl2 expression, we also detected enhanced phospho-Thr
435
RelA bound to the Cxcl2 promoter following TNFα stimulation
(Figure 6B). Levels of RelA binding to the Cxcl2 promoter, both
before and after TNFα stimulation, were comparable between the
reconstitutedMEFsandwild-typeMEFs(seeSupplementaryFig-
ure S3 at http://www.BiochemJ.org/bj/426/bj4260345add.htm).
Furthermore, consistent with the earlier results from the
reconstituted MEFs, speciﬁc Thr
435-dependent effects at the
Cxcl2 promoter were also observed in the wild-type MEFs
after TNFα stimulation, with acetylated histone H4 levels being
signiﬁcantly enhanced, whereas levels of HDAC1 present were
reduced.However,somedifferenceswereobservedbetweenthese
experimentalsystems,withacetylatedhistoneH3levelsnotbeing
seen to increase in the wild-type MEFs (Figures 6C–6E).
Since this ChIP analysis indicated that Thr
435-modiﬁed RelA is
bound to the Cxcl2 promoter, we investigated what proportion of
total promoter-associated RelA this represented. To determine
this, the ChIP samples were immunodepleted with the anti-
phospho-Thr
435 antibody prior to RelA immunoprecipitation and
PCR analysis. Signiﬁcantly, preclearing Thr
435-modiﬁed RelA
negated the TNFα-induced increase in RelA binding to the Cxcl2
promoter, but had little effect on RelA binding to the Cxcl1
promoter, indicating that a very speciﬁc pool of activated RelA
binds to and regulates the expression of Cxcl2 (Figure 6F).
Taken together, these results support the data obtained from the
reconstitutedMEFcelllinesanddemonstratethatphosphoryation
ofThr
435 playsanimportantroleintheregulationofCxcl2mRNA
expression in wild-type MEF cells following TNFα stimulation.
DISCUSSION
Although Thr
435 had been identiﬁed as a putative phosphorylation
site in the TAD of RelA, subject to dephosphorylation by
PP4, this had relied on in vitro phosphorylation assays, and no
analysis of modiﬁcation in cells was performed [27]. Therefore
we generated a phospho-speciﬁc antibody against Thr
435 that
allowed the detection of endogenous RelA phosphorylation
at this site following calyculin A treatment of U-2 OS cells
(Figure 1A). Phosphorylation was also detected following TNFα
treatment in MEF cells and at the Cxcl1, Cxcl2 and Tnfaip3
promoters following ChIP analysis (Figure 1C, Figure 6B and
Supplementary Figure S2). Although this analysis establishes
Thr
435 phosphorylation as a regulator of RelA transactivation, the
identity of the kinase responsible is currently unknown. Phospho-
site prediction algorithms identify Thr
435 as a potential CK2
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Figure 6 ChIP analysis of the murine Cxcl2 promoter in wild-type MEFs
(A, B) TNFα stimulation increases binding of RelA and RelA phosphorylated at Thr435 (P-T435) to the Cxcl2 promoter region. (C) TNFα stimulation does not signiﬁcantly increase levels of
acetylated (Ac) histone H3 (K9/14) at the Cxcl2 promoter. (D) Elevated levels of acetylated histone H4 (K12) were found at the Cxcl2 promoter following TNFα treatment. (E) HDAC1 binding to the
Cxcl2 promoter was reduced after TNFα treatment. qPCR analysis was performed using primers to the mouse Cxcl2 initiation site. (F) Depleting samples of RelA phosphorylated at Thr435 with
phospho-speciﬁc antibody prior to performing ChIP analysis negates RelA binding to the Cxcl2 promoter, but not to the Cxcl1 promoter, following TNFα treatment. All results were normalized to
input levels and control antibodies. Results are the mean enrichment levels relative to untreated cells+ −S.E.M.; (A–C) n=7, (D, E) n=4, (F) n=3. Student’s t test was performed using Prism 4
software (GraphPad). *P <0.05, **P <0.01 and ***P <0.001.
(casein kinase 2) or polo-like kinase 1 target. Interestingly, CK2
waspreviouslyshowntophosphorylateRelAatSer
529 inresponse
to TNFα treatment [20]. However, phosphorylation of Thr
435 by
CK2 could not be veriﬁed empirically during the course of the
present study (results not shown). Identiﬁcation of the Thr
435
kinase is an important question that should be investigated in
futurestudies.Furthermore,Thr
435 phosphorylationinresponseto
other NF-κB inducers is also currently unknown and will require
furtheranalysis.Thatthissiteisonlyweaklyphosphorylatedafter
TNFα stimulation in U-2 OS cells implies a possible cell-type-
speciﬁc role in vivo.
In contrast with the dramatic transcriptional effects seen with
Gal4-fusion proteins (Figure 1D), full-length RelA versions of
Thr
435 phospho-mutants did not reproduce signiﬁcant effects on
transcription, when used with a selection of standard NF-κB
reporter plasmids (see Figure 1E for the 3× κB ConA luciferase
reporterplasmid;resultsnotshownforotherplasmids).Consistent
with this, analysis of endogenous gene expression revealed that,
at least in this context, the effects of Thr
435 phosphorylation
are highly promoter-speciﬁc, suggesting that this modiﬁcation
can help to provide the speciﬁcity and selectivity required to
produce a context-dependent NF-κB transcriptional response to a
stimulus.Interestingly,theeffectsseenwithThr
435 mutationonthe
endogenousCxcl2genewerealsomirroredwithaCxcl2promoter
luciferase reporter (Figure 3E). In contrast, other members of the
CXC superfamily of genes did not display Cxcl2-like sensitivity
to RelA Thr
435 phosphorylation (Supplementary Figure S1), and
gene-expression-array analysis will be required to identify other
target genes similarly regulated by modiﬁcation at this site.
These observations suggest that it is the speciﬁc organization
of the Cxcl2 promoter that confers Thr
435 regulation. Importantly,
immunodepletionpriortoChIPanalysisrevealedthatthemajority
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of RelA bound to the Cxcl2 promoter was Thr
435-phosphorylated,
in contrast with the Cxcl1 promoter, at which most RelA was
not modiﬁed at Thr
435 (Figure 6F). Moreover, the T435D mutant
shows elevated levels of Cxcl2 promoter binding, not seen with
Cxcl1 or Tnfaip3 (Figure 3A, and Supplementary Figures 2A and
2B),suggestingthatthismodiﬁcationfacilitatesRelArecruitment
to the Cxcl2 promoter. Given the location of this motif in the
TAD, we consider it unlikely that this effect is due to an alteration
in site-speciﬁc RelA DNA binding. Rather, it is more likely to
arise through effects on transcriptional co-regulators required
to appropriately modify Cxcl2 promoter chromatin structure.
Such effects may be mediated by the co-repressor HDAC1,
whose binding to RelA is inhibited by the T435D mutation
(Figure 4G). However, we cannot rule out effects on other
interactions and it is entirely possible that Thr
435 phosphorylation
not only decreases HDAC1 binding, but also enhances binding
to an, as yet unidentiﬁed, HAT (histone acetyltransferase). We
also investigated binding of the CBP (cAMP-response-element-
binding protein-binding protein) and TIP60 (Tat-interacting
protein, 60kDa) HATs to the Thr
435 mutants as a potential
explanation for the variations in histone acetylation observed,
but no differences in their occupation of the Cxcl2 promoter were
detectedintheRelAT435D-reconstitutedcellsandnodifferences
in binding to Thr
435-mutant forms of RelA were observed (results
not shown). However, other TNFα-induced interactions with
additionalco-transcriptionalproteins,suchasSIRT6,Pin1,which
isrequiredforoptimalCxcl2expression,andRPS3[40–42],were
not investigated during the course of the present study and may
also emerge as being regulated by Thr
435 phosphorylation.
Our investigation of the consequences of RelA Thr
435
phosphorylation shows similarities and differences to previous
analyses of point mutations to known RelA post-translational
modiﬁcation sites. Phosphorylation at Ser
276 is known to play
a role in activating RelA and regulating its interaction with
either the co-activators CBP/p300 or HDAC co-repressors [43].
Reconstituting Rela
−/− MEFs, with a non-phosphorylatable
S276A mutant form of human RelA, similarly resulted in
distinctive expression proﬁles of NF-κB target genes, potentially
owing to decreased p300 recruitment [44–47]. Furthermore, the
S276A mutation was found to severely impair the ability of RelA
to rescue Rela
−/− MEFs from TNFα-mediated cell death [48], an
effect not found with Thr
435 mutation. Phosphorylation at Ser
536 is
known to affect the activity of RelA, and reconstituting Rela
−/−
MEFswithanon-phosphorylatableS536Amutantformofhuman
RelA was shown to decrease LPS-induced NF-κB activation and
also to reduce p300 recruitment, subsequently decreasing TNFα
activation [45,49]. Reconstituting Rela
−/− MEFs with a phospho-
mimickingS536DmutantproducedenhancedbindingtoTAFII31
and enhanced transcriptional activity, reciprocating effects of
IL-1-induced NF-κB activation [9]. Finally, phosphorylation at
Ser
468 has been reported to have both inhibitory and activatory
effects on transactivation, and reconstituting Rela
−/− MEFs with
a non-phosphorylatable S468A mutant form of human RelA
has been shown to have a negative effect on both IL-1- and
TNFα-induced NF-κB transactivation [19]. TNFα-induced Ser
468
phosphorylation was also found to regulate ubiquitin-mediated
proteasome-dependent removal of chromatin-bound RelA on
certain NF-κB gene targets [13]. However, this effect was not
observed for Cxcl2, suggesting that other modiﬁcations, such as
the Thr
435 phosphorylation identiﬁed in the present study, will
have a primary regulatory role.
Taking these results together with the conclusions of previous
studies, it is becoming clearer that phosphorylation of RelA helps
to programme its transcriptional functions by determining its
activity at select target genes through modulating interactions
with co-activators and co-repressors. In the present study we
haveidentiﬁedaroleforThr
435 phosphorylation,which,following
TNFα stimulation, modulates the interactions with HDAC1 and
selectively regulates NF-κB-dependent gene expression. This
adds to the number of such modulatory phosphorylation events
controlling NF-κB activity. Given the possible side effects
associated with total NF-κB inhibition as a clinical therapy,
drugs that selectively regulate RelA activity by affecting its post-
translational modiﬁcations have the potential to act as effective
therapies for the wide range of diseases associated with aberrant
NF-κB activity.
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Thr435 phosphorylation regulates RelA (p65) NF-κB subunit transactivation
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Figure S1 Expression of CXC-chemokine superfamily members
(A–F) Introduction of RelA into Rela−/− MEFs increases expression levels of Cxcl3, Cxcl4 (Pf4), Cxcl5 (GCP-2), Cxcl7 (Ppbp), Cxcl10 (IP-10) and Cxcl11. Mutating the Thr435 phospho-site
reduces the enhanced expression of Cxcl3, Cxcl4 (Pf4), Cxcl5 (GCP-2), Cxcl7 (Ppbp) and Cxcl10 (IP-10). Furthermore, induction of Cxcl7 (Ppbp) and Cxcl10 (IP-10) following TNFα treatment
is severely diminished in the T435D cell line. (G) Introduction of RelA into the Rela−/− MEFs decreases Cxcl12 expression levels and does not exhibit increased expression after TNFα treatment.
RNA was extracted from reconstituted MEF cells, either unstimulated or stimulated with TNFα (40ng/ml) for 30min. Total cDNA was prepared and qPCR analysis was performed using primers to
mouse (A) Cxcl3,( B) Cxcl4 (Pf4), (C) Cxcl5 (GCP-2), (D) Cxcl7 (Ppbp), (E) Cxcl10 (IP-10), (F) Cxcl11,( G) Cxcl12 and Gapdh control. For CXC gene family members not shown, we were unable
to detect signiﬁcant levels of expression in these cells. All results were normalized to Gapdh levels and are expressed as fold-induction relative to the level of gene expression in the control cell line.
Results are the means+ −S.E.M., n = 4. Two-way ANOVA was performed followed by a Bonferroni post-hoc test to compare replicate untreated and TNFα means, using Prism 4 software (GraphPad).
**P <0.01 and ***P <0.001.
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Figure S2 ChIP analysis of the murine Cxcl1 and Tnfaip3 promoters in reconstituted and wild-type MEFs
(A, B) Enhanced binding of RelA to the Cxcl1 and Tnfaip3 promoters following introduction of all forms of RelA into RelA−/− MEFs. (C–F) Elevated levels of RelA and RelA phosphorylated at
Thr435 (P-T435) at the Cxcl1 and Tnfaip3 promoters following TNFα treatment in wild-type MEFs. All results were normalized to input levels and control antibodies. Results are the mean enrichment
levels relative to untreated cells+ −S.E.M., n = 3. (A, B) ANOVA was performed followed by a Tukey–Kramer multiple comparisons test using Prism 4 software (GraphPad). (C–F) Student’s t test was
performed using Prism 4 software (GraphPad). *P <0.05 and **P <0.01. Grey asterisks indicate P values relative to the control cell line.
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Figure S3 Similar levels of RelA are found at the Cxcl2 promoter in
reconstituted wild-type RelA MEFs and wild-type MEFs
BindingofRelAtotheCxcl2 promoterincreasestosimilarlevelsinbothreconstitutedwild-type
RelAandwild-typeMEFsfollowingTNFα stimulation.Allresultswerenormalizedtoinputlevels
and control antibodies. Results are the mean enrichment levels relative to untreated control
cells+ −S.E.M.,n =3.Two-wayANOVAwasperformedfollowedbyaBonferronipost-hoctestto
comparereplicateuntreatedandTNFα means,usingPrism4software(GraphPad).**P <0.01.
Received 21 October 2009/14 December 2009; accepted 15 December 2009
Published as BJ Immediate Publication 15 December 2009, doi:10.1042/BJ20091630
c   The Authors Journal compilation c   2010 Biochemical Society © 2010 The Author(s)
The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Non-Commercial Licence (http://creativecommons.org/licenses/by-nc/2.5/)
which permits unrestricted non-commercial use, distribution and reproduction in any medium, provided the original work is properly cited.